Ekso Bionics® Launches Ekso GT with Smart Assist
RICHMOND, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced it recently has shipped the first device incorporating SmartAssist, its next generation gait therapy software, allowing the company to expand the range of patients who can participate in robotic therapy.
The SmartAssist technology, which is currently available for Ekso GT devices in Europe, offers new options to therapists for customizing training in gait and balance. The SmartAssist software allows physical therapists to vary the support of the device for each leg independently - from full power to free walking - and thereby meet the specific needs of patients. This capability enables the Ekso GT to rehabilitate a larger range of patients, from those too weak to walk to those who are nearly independent.
“SmartAssist has definitely made a change to how we use the exoskeleton and broadened the spectrum of conditions we can use it for,” commented Louis Martinelli, Neurological Physiotherapist at Hobbs Rehabilitation in Winchester, England. “The therapists can now adjust the settings to vary the support we give, not only to the swing phase but the stance phase of gait, giving the participant access to an optimal walking pattern.”
The Ekso GT with SmartAssist is a comprehensive gait therapy tool that can support a broad spectrum of patients. The technology allows patients to be more actively engaged in their rehabilitation than ever before, enabling more activity with higher intensity than previously possible.
“Ekso GT with SmartAssist software was developed to expand the applications for use within clinics. The addition of pre-gait exercises have facilitated earlier mobility for some patients who could not have otherwise been mobile and our new FreeGait advanced mode can help patients progress to community ambulation,” commented Thomas Looby, chief executive officer of Ekso Bionics. “We are excited to offer this as another life changing solution for patients who use our exoskeletons for rehabilitation.”
The SmartAssist software is not yet available in the United States.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first FDA cleared exoskeleton cleared for use with stroke and spinal cord injuries from L5 to C7. The Ekso GT with smart Variable Assist™ (marketed as SmartAssist outside the U.S.) software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 55 million steps in over 120 rehabilitation institutions around the world.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 email@example.com Investor Contact: Debbie Kaster 415-937-5403 firstname.lastname@example.org
Released October 4, 2016